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Objective: To evaluate the impact of enzyme replacement therapy for Gaucher Disease on
clinical and laboratory parameters after two, ﬁve and ten years of treatment.
Methods: Data were collected from patient records and analyzed using BioEstat software (ver-
sion 5.0). Student’s t-test, Analysis of Variance (ANOVA), Wilcoxon test and Kruskal–Wallis
test  were used for statistical analysis. Hepatomegaly and splenomegaly were analyzed using
the  Kappa test.
Results: There was a signiﬁcant increase in hemoglobin levels (p-value <0.01) and platelet
counts (p-value = 0.01) within two years of therapy. At the same time, the frequencies of
splenomegaly (p-value <0.01) and hepatomegaly (p-value <0.05) reduced. These results were
similar at ﬁve and ten years of enzyme replacement therapy.
Conclusions: There are substantial and quick (within two years) laboratory and clinical
responses to enzyme replacement therapy. These improvements continue as long as enzyme
replacement therapy is administered every two weeks, as recommended by the literature.©  2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
deﬁciency is caused by a mutation in the -glucosidase gene,
2ntroduction
aucher Disease (GD) is a recessive autosomal hereditary dis-
rder classiﬁed as an inborn error of the metabolism. It is the
ommonest lysosomal storage disease and was the ﬁrst one
or which a speciﬁc treatment was developed. It occurs due to
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eserved.a deﬁciency in the activity of the enzyme -glucosidase and is
characterized by the intra-lysosomal accumulation of gluco-
cerebroside in reticuloendothelial system cells.1 The enzyme Medicina da Universidade Federal do Pará, Prac¸a Camilo Salgado,
located on chromosome 1 (GBA1). GD is a rare pan-ethnic
disorder, but it presents a high incidence among Ashkenazi
Jews. The worldwide incidence is estimated at from 1:50,000
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
oter.
amount of enzyme (IU/kg) given to each patient during the
study intervals.
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to 1:100,000 live newborns,3 whereas the incidence in the Jew-
ish population ranges from 1:400 to 1000 live newborns in the
USA.4
Clinically, GD presents a wide variety of signs and symp-
toms and is classiﬁed as non-neuronopathic (Type 1) or
neuronopathic (Types 2 and 3). Type 1 GD (95% of cases)
usually manifests with splenomegaly, hepatomegaly, ane-
mia, thrombocytopenia, bone disease and delayed growth.5
Type 2 is characterized by a precocious and fast brainstem
degeneration;3 these patients do not respond to treatment
and death occurs within the ﬁrst two years of life.6 Type
3 GD patients have a slow evolving neurologic disease and
usually present with seizures, eye movement  abnormalities
and mild systemic involvement with mean survival being to
the third decade of life.7 The treatment of GD is based on
enzyme replacement therapy (ERT), initially by alglucerase,8
but this was widely substituted by its therapeutic equivalent,
imiglucerase.9 Accordingly to Brazilian Ministry of Health,
there were 610 ERT-dependent patients in the country in 2010.
There are no data concerning the national incidence of the
disease.10
The objective of this study was to evaluate the impact of
ERT on clinical and laboratory parameters of GD through a
comparative analysis of data at diagnosis and after two, ﬁve
and ten years of treatment in a population from Pará State,
Brazil.
Methods
This was an analytical observational longitudinal retrospec-
tive study (historical cohort) of patients at the Fundac¸ão
Centro de Hemoterapia e Hematologia do Pará (HEMOPA),
Belém, Pará State. The patients were diagnosed with non-
neuronopathic (Type 1) and neuronopathic (Type 3) GD and
were treated and followed-up at HEMOPA between 2000 and
2011.
The inclusion criteria for the study were to have a con-
ﬁrmed diagnosis of GD and to be treated and followed-up at
HEMOPA for at least 24 months. Clinical records prior to treat-
ment were also necessary.
Data were collected from patient records using a question-
naire designed for this study. This questionnaire included the
following items: demographic characteristics, genetic proﬁle,
ERT dose, hematological aspects (hemoglobin levels, white
cell count and platelet count) and clinical manifestations
(splenomegaly, hepatomegaly and neurological symptoms).
Data were collected at four different time points: at diagnosis
and after two, ﬁve and ten years of ERT. Diagnosis was deﬁned
as the time when Gaucher’s cells and/or the -glucosidase
deﬁciency were identiﬁed. Data concerning the two-, ﬁve-
and ten-year time points were collected based on the ﬁrst
administration of ERT. This study was approved by the Ethics
Committee of HEMOPA (register # 0016.0.324.324-11).
Statistical  analysisData were placed in tables and graphs drawn using the
Microsoft Excel 2010 software. ERT doses, hemoglobin levels,
white cell count and platelet count over time were analyzed 2 0 1 4;3  6(5):345–350
using Student’s t-test, Analysis of Variance (ANOVA), Wilcoxon
and Kruskal–Wallis tests, as applicable. Splenomegaly and
hepatomegaly were analyzed using the Kappa test. All results
with p-values <0.05 were considered signiﬁcant and tests were
carried out using the BioEstat (version 5.0) software.
Results
Demographic  characteristics
Records of 24 patients diagnosed with GD were found and of
these, 13 met  the inclusion criteria. Eight were female (61.50%)
and ﬁve were male patients (38.50%). Ages ranged from four to
43 years (mean: 24.53 years). Thirteen patients (100%) were on
ERT for two years; nine (69.23%) had completed ﬁve years of
treatment and six patients (46.15%) had been treated for ten
years. In order to preserve patients’ identity, they are num-
bered 1 through 13.
At diagnosis, the mean age of patients was 13.49 years old
(±30.10 years). Eight patients (61.53%) were under 12 years
old at diagnosis (patients 1, 3, 4, 5, 8, 11, 12 and 13), three
(23.07%) were women over 12 years (patients 6, 9 and 10) and
two (15.4%) were men  over 12 years (patients 2 and 7). Only
one patient (7.7%) was diagnosed with Type 3 GD; this patient
died at age 22 after ten years of treatment. All other patients
were diagnosed as Type 1.
Genetic  proﬁle
Ten patients (76.92%) were submitted to GBA1 mutation anal-
ysis with the frequencies of the mutations listed in Fig. 1.
ERT  dose
ERT was administered every two weeks. Table 1 shows theN370S/L444P + V460V ?/?
Figure 1 – Frequency of mutations in patients with GD
submitted to GBA1 analysis at HEMOPA.
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Table 1 – Enzyme replacement therapy dose
administered (IU/kg) to patients with Gaucher Disease
by study interval.
Patient At start 2 years 5 years 10 years
1 27.9 25.0 28.0 30.0
2 30.0 30.0 26.0 –
3 36.6 40.0 – –
4 30.0 30.0 – –
5 18.4 42.1 – –
6 33.3 37.1 30.0 15.0
7 44.0 44.0 41.0 37.0
8 22.0 61.0 54.0 –
9 35.0 24.6 27.0 15.0
10 15.0 29.0 29.0 –
11 37.7 37.7 26.9 15.0
12 32.4 40.0 – –
13 29.4 13.6 40.0 85.7
There was no statistical difference in the dose received between
any of the study intervals (p-value = 0.78). Mean dose of all periods
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Table 3 – White cell count (× 109/L) of patients under
enzyme replacement therapy for Gaucher Disease by
study interval.
Patients At diagnosis 2 years 5 years 10 years
1 4.20 3.40 3.13 4.35
2 10.60 9.93 9.58 –
3 1.80 1.06 – –
4 4.56 6.30 – –
5 6.71 5.66 – –
6 11.30 11.70 13.80 13.10
7 5.50 15.40 10.80 10.70
8 12.30 17.80 6.91 –
9 4.40 5.30 4.81 7.00
10 8.80 5.80 6.50 –
11 3.00 2.90 3.88 4.23together was 32.88 IU/kg.
aboratory  parameters
able 2 presents hemoglobin levels (g/dL) at diagnosis and
fter two, ﬁve and ten years of treatment.
The mean hemoglobin level at diagnosis (9.9 g/dL) and after
wo years of treatment (12.4 g/dL) were compared using Stu-
ent’s t-test. The mean difference between these two periods
2.5 g/dL) was statistically signiﬁcant (p-value = 0.0039; 95%
onﬁdence interval: 0.0762–4.15). ANOVA, however, did not
how statistical difference when the intervals of 2, 5 and 10
ears were compared. On the other hand, hemoglobin levels
t 5 and 10 years were signiﬁcantly higher than the levels at
iagnosis (p-value <0.01 for both periods).
Table 3 shows the total white cell count in the different
tudy intervals.
No statistical signiﬁcance was found for the white cell
ount between any of the study intervals.Table 4 presents the platelet counts at diagnosis and after
wo, ﬁve and ten years of ERT.
Table 2 – Hemoglobin levels (g/dL) of patients under
enzyme replacement therapy for Gaucher Disease by
study interval.
Patient At diagnosis 2 years 5 years 10 years
1 10.0 14.0 11.4 13.4
2 8.2 16.1 13.9 –
3 10.5 9.6 – –
4 12.2 11.8 – –
5 12.6 13.8 – –
6 10.6 12.0 10.5 12.2
7 12.8 12.2 13.4 13.9
8 9.5 11.9 11.3 –
9 8.2 13.6 13.8 14.0
10 9.4 10.0 12.3 –
11 7.4 13.8 13.6 14.6
12 8.7 10.7 – –
13 9.0 11.4 12.5 10.512 6.18 9.30 – –
13 2.90 3.00 3.94 3.00
The difference in platelet counts between diagnosis and
after two years of treatment, evaluated using the Wilcoxon
test (non-normal distribution at diagnosis), was statistically
signiﬁcant (p-value = 0.01). The differences between the other
periods were not statistically signiﬁcant.
Clinical  manifestations
On analyzing splenomegaly, two patients were excluded
because they had been submitted to splenectomy prior to ERT.
All of the 11 remaining patients presented splenomegaly at
diagnosis, detected either by physical exam or radiological
imaging. After two years of ERT, 63.63% of the cases presented
with splenomegaly. This reduction was statistically signiﬁcant
(p-value <0.05). A reduction, albeit non-signiﬁcant, was found
in the frequency of splenomegaly comparing patients after
only two years of treatment and after ﬁve and ten years of
treatment.
Similar results were found concerning hepatomegaly. Of
the 13 patients, 69.23% had hepatomegaly at diagnosis. At
the end of two  years of ERT, only 30.77% continued with any
degree of hepatomegaly. This reduction was signiﬁcant (p-
value <0.05). There was a further reduction in the number of
Table 4 – Platelet count (× 109/L) of patients under
enzyme replacement therapy for Gaucher Disease by
study interval.
Patients At diagnosis 2 years 5 years 10 years
1 90.0 87.0 74.9 121.0
2 105.0 348.0 378.0 –
3 20.0 20.3 – –
4 240.0 205.0 – –
5 117.0 165.0 – –
6 390.0 336.0 317.0 127.0
7 200.0 232.0 222.0 312.0
8 112.0 258.0 204.0 –
9 87.0 165.0 178.0 186.0
10 120.0 154.0 128.0 –
11 59.0 101.0 71.4 131.0
12 92.4 158.0 – –
13 53.0 105.0 130.0 1560
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patients with hepatomegaly at 5 and 10 years of treatment,
but the differences were not statistically signiﬁcant.
Neurological symptoms were noticed only in the Type 3
patient in the study sample. This patient presented seizures,
tremors of the extremities, dyslalia and difﬁculties walking
during all the period of ERT (10 years).
Discussion
GD is usually described as a pan-ethnic disease, attacking men
and women in equal proportions. However, this study pre-
sented a higher prevalence of female (61.5%) compared to male
patients (38.5%). This data is similar to a study by Sobreira &
Bruniera,3 who showed a higher prevalence (67.8%) of female
patients, and differs from Ferreira et al.,1 who reported a slight
predominance of male patients. This is attributed to the small
sample size common when studying rare conditions. No data
relating the patients to Ashkenazi parentage were found.
Mean age at diagnosis was slightly higher than that
reported by Sobreira and Bruniera (11.8 years old)3 and lower
than that in the study of Charrow et al. (17.4 years old).11
Giraldo et al.12 reported a mean age at diagnosis of 27.4 years
old. Earlier manifestations of the disease are typical for Latin-
American populations; in these patients, the ﬁrst symptoms of
GD occur at 11 years of age and can be more  severe.13 Such dif-
ferences show that GD can present at differing ages in different
populations and is an expression of the disease’s heterogene-
ity.
The N370S mutation, in 70% of the individuals submit-
ted to GBA1 analysis, was the most common in this study
sample. This data is similar to a study of 1698 patients from
the Gaucher Registry,11 in which 84% of individuals had at
least one N370S allele; however, 23% were homozygous for
this mutation, different to the current study, in which no
homozygous individuals were found. The second most fre-
quent mutation was L444P, which occurred in 50% of the
sample. This frequency is slightly higher than that of Char-
row et al. (30%),11 Kaplan et al. (34%)5 and considerably higher
than that of Andersson et al. (23.7%).14 Even so, no homozy-
gous individuals with the L444P mutation were found in this
sample. No other mutation that is considered common in the
literature,6 such as 84GG and IVS+1, was found. On the other
hand, the V460V mutation, which is not considered a common
mutation, was associated to the L444P mutation.
The divergences between these data are most likely due to
the fact that the aforementioned studies gathered informa-
tion from ﬁve continents and that Latin-America represented
a small portion of the total. A study of just Latin-American
patient records in the Gaucher Registry13 found a low fre-
quency of L444P homozygosis. In the same study, 82% of
individuals had at least one N370S allele, but only a small
portion of them was homozygous. A small study in Santa
Catarina State, Brazil1 corroborates these ﬁndings; 60% of
individuals were heterozygous for the N370S mutation and
there was only one homozygous case. The L444P mutation
was found in 30% of individuals and there was one case
of homozygosis. The differences between studies in Brazil,
Latin-America and worldwide show that Brazilian and Latin-
American patients have a genetic proﬁle that differs from 2 0 1 4;3  6(5):345–350
that of patients from other nations with such differences
being expressed as diverse phenotypic presentations of the
disease.
Furthermore, a study with 48 Brazilian patients from dif-
ferent regions of the country found seven different previously
unknown mutated sequences of GBA. Five were missense
changes (S125N, F213L, P245T, W378C, D399H), one was an in-
frame insertion and the other one was a splicing mutation in
a complex allele (L461P + IVS10 + 1G > T). These data reinforce
the genetic heterogeneity of Brazilian GD patients as was also
found in the current research. This study also suggests that
the presence of the N370S allele would be a protective factor
for neurological manifestations.15 Indeed, the only Type 3 GD
patient presented the L444P allele, along with an unknown
allele.
The ERT infusion periodicity was constant during all inter-
vals of the treatment. The mean dose administered was
slightly higher than the dose recommended by the Brazil-
ian Consensus for the treatment of GD (32.88 IU/kg versus
30.0 IU/kg).7 This small difference is due to the fact that the
dose registered in patients’ records was the total amount and
the division in respect to the patients’ weight frequently did
not result in an exact value. Furthermore, individual varia-
tions observed in Table 1 reﬂect: 1 – the levels of the severity
of the disease that require higher or lower doses, as explained
by Goker-Alpan;16 2 – the need of new adjustments to the
dose due to a dramatic reduction in the stock of imiglucerase
after a viral infection that occurred in 2009;17 3 – the retake
of the doses recommended by the Therapeutic Guidelines for
GD of the Brazilian Ministry of Health,18 after the stock was
replenished.
In the study sample, ERT was effective in raising the
hemoglobin levels in the ﬁrst two years of treatment and in
keeping them stabile during all the period that the enzyme
was administered. This was also true even when the patients
were under 12 years old at diagnosis. The improvement in ane-
mia  and the stabilization of hemoglobin levels have already
been demonstrated in a two-year study of 148 patients in
which the number of anemic patients drastically fell within
the ﬁrst six months of starting ERT.3 The results of the
hemoglobin levels at the end of two years of treatment
are in accordance with the therapeutic goal proposed by
Weinreb et al.,19 i.e., hemoglobin ≥11 g/dL in under 12-year-
old patients (87.5% in the current study), ≥11 g/dL in adult
women (not achieved by only one woman in this study) and
≥12 g/dL in adult men  (achieved by both men  in the current
study).
The platelet count also rose signiﬁcantly by the end of two
years of ERT. Weinreb et al.19 divided the therapeutic goal
for platelet count into three groups: patients with count at
diagnosis >120.0 × 109/L must remain in this range, patients
with counts ranging from 60.0 × 109/L to 120.0 × 109/L must
achieve counts over 120.0 × 109/L, and patients with counts
<60.0 × 109/L must increase their count by twofold. In the
study sample, the results were satisfactory, as nine of the
13 patients (69.23%) achieved the therapeutic goal within two
years of treatment. For the ﬁrst two groups, only Patient 1, who
belonged to the second group, did not reach the therapeutic
goal. However, none of the patients in the third group tripled
their platelet counts within two years of ERT. These patients
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resent a more  severe disease and respond slowly and gradu-
lly (or even unsatisfactorily) to therapy as far as the platelet
ount is concerned.5
Nonetheless, ERT is capable of keeping the disease stable
ver the years in most patients. This is evidenced by the nor-
al  mean hemoglobin levels and platelet counts at the end of
ve and ten years of treatment. This effect was observed in a
tudy with 887 children whose hemoglobin levels and platelet
ounts improved in the ﬁrst two years and remained stable
ver eight years of observation.14 Despite the presence of adult
atients in the study sample, our results suggest that the efﬁ-
acy of ERT is similar in different age groups in relation to
hese two hematological parameters.
Additionally, the results suggest that a lower-dose regimen
i.e., approximately 30 IU/kg every two weeks) is as effective in
eaching the therapeutic goals as a high-dose regimen, as orig-
nally proposed by Barton et al.8 (60 IU/kg every two weeks).
his brings an economic advantage in non-wealthy nations,
uch as Brazil, allowing them to reserve high-dose regimens
or critically symptomatic patients who  need a faster recovery,
imilar to what is reported in Israel.20
The absence of statistical signiﬁcance in the white cell
ount is probably due to extremely variable results between
ndividuals, i.e., while some presented leukopenia, oth-
rs presented leukocytosis. Leukocytosis is not unexpected
n GD patients as they are more  likely to acquire infec-
ions. Furthermore, the leukocyte function is disturbed in
D due to substrate accumulation in these cells, especially
he macrophage/monocyte lineage, inherent to the disease
hysiopathology.21 Additionally, leukopenia is usually not
evere and rarely requires any intervention, making the
hite cell count a non-speciﬁc parameter in the follow-up of
atients.6
Similar to the study by Ferreira et al.,1 splenomegaly was
ound in 100% of patients (splenectomized patients were not
ncluded) when clinical and radiological methods to detect
his alteration are considered. Despite the signiﬁcant reduc-
ion in the number of patients presenting with splenomegaly
fter two years of ERT, it was not possible to determine
hether there was a reduction in volume in patients who still
resented this alteration, as most records did not state the
egree of splenomegaly and, when they did, the data were not
tandardized, precluding a more  accurate analysis. Consid-
ring that in subsequent periods there was reduction in the
umber of patients with splenomegaly, even though not statis-
ically signiﬁcant, the authors believe a reduction in the spleen
olume also occurred in the ﬁrst two years of ERT, similar to
hat is reported in the literature.
The number of patients with hepatomegaly had decreased
y the end of two years of ERT similar to the study of Sobreira
 Bruniera;3 however, in that study, the reduction in liver vol-
me  occurred primarily between the 12th and 18th months
f ERT. There was no statistically signiﬁcant reduction in the
ollowing periods which shows the early response to ERT in
espect to hepatomegaly (within 2 years).
ERT was inefﬁcient to control neurological symptoms in
he only Type 3 patient in the study. Symptoms of this patient
ersisted despite increases in dose. This case exempliﬁes the
igher severity of Type 3 GD as already reported by Goker-
lpan16 and Cox.17
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Conclusion
ERT has an important impact on improving hemoglobin levels
and platelet counts. These parameters respond to treatment
in the initial phase of drug treatment (within 2 years) and
the response is maintained as long as ERT is administered
every two  weeks accordingly to the standard regimen pro-
posed in the literature. Hepatomegaly and splenomegaly also
respond signiﬁcantly to ERT within two years of treatment. As
splenomegaly is the most frequent manifestation, the pres-
ence of this sign in a patient with cytopenia should lead the
attending physician to consider GD as one of the differen-
tial diagnosis. Due to the wide range of manifestations, the
treatment of GD and follow-up must be performed by a mul-
tidisciplinary team.
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